why choose us

First received: October 11, 2023

Clinical Trial: Mirdametinib in Histiocytic Disorders

Study Status: Completed

Recruit Status: RECRUITING

Condition: Langerhans Cell Histiocytosis (LCH)

Study Type: INTERVENTIONAL


Official Title: A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

Brief Summary: The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.

Read more